SCHEMBL14320504

SCHEMBL14320504

COC(=O)c1cccc(-c2nc(Nc3ccc4c(c3)NC(=O)CCC4)c3[nH]ncc3n2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.44
ABCG2 Q9UNQ0 3/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
CRBN Q96SW2 1/20 0.42
INSR P06213 1/20 0.41
MET P08581 1/20 0.41
BTK Q06187 1/20 0.41
ABCB1 P08183 1/20 0.40
ROCK2 O75116 4/20 0.39
SYK P43405 3/20 0.39
JAK2 O60674 1/20 0.39
ABCC1 P33527 1/20 0.38
PDGFRB P09619 1/20 0.38
PIK3CA P42336 1/20 0.38
CLK2 P49760 1/20 0.37
BLK P51451 1/20 0.37
CSNK2A1 P68400 1/20 0.37
STK3 Q13188 1/20 0.37
ROCK1 Q13464 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320820 0.95 CRBN (0.48) PDE5AABCG2KDM4EMAPTCRBN
SCHEMBL14320613 0.92 BTK (0.42) ABCG2INSRMETBTKROCK2
SCHEMBL14320319 0.87 MEN1 (0.43) PDE5AABCG2CRBNBTKROCK2
SCHEMBL14320571 0.87 CRBN (0.54) PDE5AABCG2KDM4EMAPTCRBN
SCHEMBL15651130 0.85 CYP1A2 (0.47) KDM4EMAPTINSRMETCLK4
SCHEMBL14320426 0.85 SYK (0.44) ABCG2CRBNINSRMETABCB1
SCHEMBL14320404 0.85 LMNA (0.52) PDE5AABCG2KDM4EMAPTCRBN
SCHEMBL14320889 0.85 SYK (0.46) PDE5AABCG2KDM4EMAPTABCB1
SCHEMBL15650996 0.84 JAK1 (0.41) KDM4EINSRMETBTKSYK
SCHEMBL17095053 0.82 SYK (0.46) INSRMETBTKROCK2SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK PDE5A 1895/4885ABCG2 3810/4885KDM4E 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.